Assembly Biosciences (Assembly Biosciences) Debt-to-Equity : 0.06 (As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

What is Assembly Biosciences Debt-to-Equity?

Assembly Biosciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.22 Mil. Assembly Biosciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.12 Mil. Assembly Biosciences's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $41.10 Mil. Assembly Biosciences's debt to equity for the quarter that ended in Dec. 2023 was 0.06.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Assembly Biosciences's Debt-to-Equity or its related term are showing as below:

ASMB' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.04 Med: 0.04 Max: 0.06
Current: 0.06

During the past 13 years, the highest Debt-to-Equity Ratio of Assembly Biosciences was 0.06. The lowest was 0.04. And the median was 0.04.

ASMB's Debt-to-Equity is ranked better than
69.35% of 1070 companies
in the Biotechnology industry
Industry Median: 0.145 vs ASMB: 0.06

Assembly Biosciences Debt-to-Equity Historical Data

The historical data trend for Assembly Biosciences's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Assembly Biosciences Debt-to-Equity Chart

Assembly Biosciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.05

0.04

0.06

Assembly Biosciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.04	0.04	0.03	0.02	0.06

Competitive Comparison of Assembly Biosciences's Debt-to-Equity

For the Biotechnology subindustry, Assembly Biosciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Assembly Biosciences's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Assembly Biosciences's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Assembly Biosciences's Debt-to-Equity falls into.

Assembly Biosciences Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Assembly Biosciences's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.22	+	1.122)	/	41.097
	=	0.06

Assembly Biosciences's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.22	+	1.122)	/	41.097
	=	0.06

Assembly Biosciences (NAS:ASMB) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Assembly Biosciences Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Assembly Biosciences's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Assembly Biosciences (Assembly Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Assembly Biosciences Inc (NAS:ASMB) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

V7B1:Germany

Address

331 Oyster Point Boulevard, Fourth Floor, South San Francisco, CA, USA, 94080

Website

https://www.assemblybio.com

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, that are designed to restore health to a dysbiotic microbiome. The firm's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Its program targets high-recurrence genital herpes associated with herpes simplex virus type 2 (HSV-2) infection and research programs focused on the discovery of novel antivirals to treat devastating viral diseases, including hepatitis delta virus (HDV) and transplant-related herpesviruses.

Executives

Alexander Schornstein	10 percent owner	KAISER-FRIEDRICH-ALLEE 2, AACHEN 2M 52074
Nicole S White	officer: Chief Manufacturing Officer	C/O ASSEMBLY BIOSCIENCES, INC., 331 OYSTER POINT BLVD., FOURTH FLOOR, SOUTH SAN FRANCISCO CA 94080
Gilead Sciences Inc	10 percent owner	333 LAKESIDE DR, FOSTER CITY CA 94404
Jason A Okazaki	officer: Chief Legal & Business Officer	C/O ASSEMBLY BIOSCIENCES, INC., 331 OYSTER POINT BLVD, FOURTH FLOOR, SOUTH SAN FRANCISCO CA 94080
Delaney William E Iv	officer: CSO, Virology	C/O ASSEMBLY BIOSCIENCES, INC., 331 OYSTER POINT BLVD, FOURTH FLOOR, SOUTH SAN FRANCISCO CA 94080
Jeanette M Bjorkquist	officer: Principal Accounting Officer	C/O ASSEMBLY BIOSCIENCES, INC., 331 OYSTER POINT BLVD, FOURTH FLOOR, SOUTH SAN FRANCISCO CA 94080
John G Mchutchison	director, officer: CEO and President	333 LAKESIDE DRIVE, FOSTER CITY X1 94404
Michael P. Samar	officer: See Remarks	C/O ASSEMBLY BIOSCIENCES, INC., 11711 N. MERIDIAN ST. SUITE 310, CARMEL IN 46032
Luisa M Stamm	officer: Chief Medical Officer	C/O ASSEMBLY BIOSCIENCES, INC., 11711 N. MERIDIAN ST, SUITE 310, CARMEL IN 46032
Michael Houghton	director	C/O ASSEMBLY BIOSCIENCES, INC., 331 OYSTER POINT BLVD., FOURTH FLOOR, SOUTH SAN FRANCISCO CA 94080
Lisa Johnson-pratt	director	C/O TRACON PHARMACEUTICALS, INC., 4350 LA JOLLA VILLAGE DRIVE, SUITE 800, SAN DIEGO CA 92122
Jacqueline Sybil Papkoff	officer: See remarks	C/O ASSEMBLY BIOSCIENCES, INC., 11711 N. MERIDIAN STREET, SUITE 310, CARMEL IN 46032
Gina Consylman	director	C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Richard James Colonno	officer: Chief Science Officer	ASSEMBLY BIOSCIENCES, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Thomas Joseph Russo	officer: CFO	C/O ASSEMBLY BIOSCIENCES, INC., 11711 N MERIDIAN ST, SUITE 310, CARMEL IN 46032